Limits...
High USP22 expression indicates poor prognosis in hepatocellular carcinoma.

Tang B, Tang F, Li B, Yuan S, Xu Q, Tomlinson S, Jin J, Hu W, He S - Oncotarget (2015)

Bottom Line: Kaplan-Meier analysis showed that elevated USP22 expression predicted poorer overall survival and recurrence-free survival.Multivariate analyses revealed that USP22 expression is an independent prognostic parameter in HCC.These findings provide evidence that high USP22 expression might be important in tumor progression and serves as an independent molecular marker for poor HCC prognosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.

ABSTRACT
Ubiquitin-specific protease 22 (USP22) removes ubiquitin from histones, thus regulating gene transcription. The expression frequency and expression levels of USP22 were significantly higher in hepatocellular carcinoma (HCC) than in normal liver tissues. High USP22 expression in HCC was significantly correlated with clinical stage and tumor grade. Kaplan-Meier analysis showed that elevated USP22 expression predicted poorer overall survival and recurrence-free survival. High USP22 expression was also associated with shortened survival time in patients at advanced tumor stages and with high grade HCC. Multivariate analyses revealed that USP22 expression is an independent prognostic parameter in HCC. These findings provide evidence that high USP22 expression might be important in tumor progression and serves as an independent molecular marker for poor HCC prognosis. Thus, USP22 overexpression identifies patients at high risk and represents a novel therapeutic molecular target for this tumor.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical staining for USP22 in HCC and normal adjacent hepatic tissuesThe level of USP22 protein was determined by immunohistochemical staining using a USP22 antibody, and the nuclei were counterstained with hematoxylin. (A) USP22 was overexpressed in the cytoplasm in HCC tissue; (B) USP22 was expressed at negative levels in matched normal hepatic tissues from the same patient (100×). (C) and (D) are images recorded at higher magnification (400×) from the areas shown in boxes in (A) and (B), respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494964&req=5

Figure 7: Immunohistochemical staining for USP22 in HCC and normal adjacent hepatic tissuesThe level of USP22 protein was determined by immunohistochemical staining using a USP22 antibody, and the nuclei were counterstained with hematoxylin. (A) USP22 was overexpressed in the cytoplasm in HCC tissue; (B) USP22 was expressed at negative levels in matched normal hepatic tissues from the same patient (100×). (C) and (D) are images recorded at higher magnification (400×) from the areas shown in boxes in (A) and (B), respectively.

Mentions: Immunohistochemical results show that the positive USP22 staining was mainly located in the cytoplasm and was overexpressed in HCC tissue, whereas normal matched liver tissues showed negative expression (Fig. 7). To further assess survival and avoid the problems of multiple cut point selection, ROC curve analysis was employed to determine a cutoff score for USP22 expression. As shown in Figs. 8A and 8B, the USP22 cutoff score for OS and PFS in the training set was 3.5 (p = 0.000 and p = 0.001, respectively). We thus selected a USP22 expression score of 3.5 (>3.5 VS.≤ 3.5) as the uniform cutoff point for survival analysis in the test set.


High USP22 expression indicates poor prognosis in hepatocellular carcinoma.

Tang B, Tang F, Li B, Yuan S, Xu Q, Tomlinson S, Jin J, Hu W, He S - Oncotarget (2015)

Immunohistochemical staining for USP22 in HCC and normal adjacent hepatic tissuesThe level of USP22 protein was determined by immunohistochemical staining using a USP22 antibody, and the nuclei were counterstained with hematoxylin. (A) USP22 was overexpressed in the cytoplasm in HCC tissue; (B) USP22 was expressed at negative levels in matched normal hepatic tissues from the same patient (100×). (C) and (D) are images recorded at higher magnification (400×) from the areas shown in boxes in (A) and (B), respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494964&req=5

Figure 7: Immunohistochemical staining for USP22 in HCC and normal adjacent hepatic tissuesThe level of USP22 protein was determined by immunohistochemical staining using a USP22 antibody, and the nuclei were counterstained with hematoxylin. (A) USP22 was overexpressed in the cytoplasm in HCC tissue; (B) USP22 was expressed at negative levels in matched normal hepatic tissues from the same patient (100×). (C) and (D) are images recorded at higher magnification (400×) from the areas shown in boxes in (A) and (B), respectively.
Mentions: Immunohistochemical results show that the positive USP22 staining was mainly located in the cytoplasm and was overexpressed in HCC tissue, whereas normal matched liver tissues showed negative expression (Fig. 7). To further assess survival and avoid the problems of multiple cut point selection, ROC curve analysis was employed to determine a cutoff score for USP22 expression. As shown in Figs. 8A and 8B, the USP22 cutoff score for OS and PFS in the training set was 3.5 (p = 0.000 and p = 0.001, respectively). We thus selected a USP22 expression score of 3.5 (>3.5 VS.≤ 3.5) as the uniform cutoff point for survival analysis in the test set.

Bottom Line: Kaplan-Meier analysis showed that elevated USP22 expression predicted poorer overall survival and recurrence-free survival.Multivariate analyses revealed that USP22 expression is an independent prognostic parameter in HCC.These findings provide evidence that high USP22 expression might be important in tumor progression and serves as an independent molecular marker for poor HCC prognosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.

ABSTRACT
Ubiquitin-specific protease 22 (USP22) removes ubiquitin from histones, thus regulating gene transcription. The expression frequency and expression levels of USP22 were significantly higher in hepatocellular carcinoma (HCC) than in normal liver tissues. High USP22 expression in HCC was significantly correlated with clinical stage and tumor grade. Kaplan-Meier analysis showed that elevated USP22 expression predicted poorer overall survival and recurrence-free survival. High USP22 expression was also associated with shortened survival time in patients at advanced tumor stages and with high grade HCC. Multivariate analyses revealed that USP22 expression is an independent prognostic parameter in HCC. These findings provide evidence that high USP22 expression might be important in tumor progression and serves as an independent molecular marker for poor HCC prognosis. Thus, USP22 overexpression identifies patients at high risk and represents a novel therapeutic molecular target for this tumor.

No MeSH data available.


Related in: MedlinePlus